Avricore Health Engages Oak Hill Financial to Provide Investor Relations and Advisory Services
September 13 2021 - 7:00AM
AVRICORE HEALTH INC. (TSXV: AVCR) (the
"
Company" or “
AVCR”) announces
that it has appointed Oak Hill Financial Services Inc. (“Oak Hill”)
to provide the Company with investor relations and advisory
services. Oak Hill is a Toronto-based financial services company
that assists companies in enhancing their corporate profile.
Under the engagement, Oak Hill will be paid a fee of $12,000 per
month for an initial three months. More specifically, Oak Hill will
provide services such as drafting marketing materials and reaching
out to its Canadian investor network to expand Avricore’s
visibility in the financial community. In certain circumstances,
additional services may be provided to the Company by Oak Hill and
additional contingent consideration for such services may be
applicable.
“We are really excited by Oak Hill’s track record of success in
our sector, and they share our passion for the mission behind our
core business,” said Hector Bremner, CEO of Avricore Health. “I’m
confident in their team’s abilities to help us achieve our
market-based goals.”
The Company has, subject to regulatory approval, granted Oak
Hill stock options to purchase 250,000 common shares of the Company
at an exercise price of $0.17 per share for a period of eighteen
months. The engagement of Oak Hill is subject to TSX Venture
Exchange approval.
About Oak Hill Financial
Oak Hill Financial is a leading Canadian marketing and
distribution firm, focused on IIROC retail brokerage networks,
servicing both asset managers and public companies. Oak Hill
Financial’s experienced team of former asset management
wholesalers, research analysts and capital market professionals
specializes in building credibility for their clients to a network
of over 10,000 Canadian IIROC retail brokers and over 300 North
American funds.
About HealthTab™
HealthTab™ is a turnkey point-of-care testing solution that
combines best-in-class point-of-care technologies with a secure,
cloud-based platform for tackling pressing global health issues.
With just a few drops of blood from a finger prick, the system
generates lab-accurate results on the spot and data is reported in
real time. The test menu includes up to 23 key biomarkers for
screening and managing chronic diseases, such as diabetes and heart
disease (e.g., HbA1c, Lipid Profile, eGFR). HealthTab™ has also
recently added capabilities for bacterial and viral tests, such as
strep and COVID-19. The HealthTab™ network model is unlike
anything in pharmacy today. It gives knowledgeable and trusted
pharmacists a greater role in primary care delivery, while
empowering patients to take more control of their health. It also
reduces costs and waiting times and provides many potential revenue
streams including equipment leasing & consumables, direct
access testing, disease prevention & management programs,
sponsored health programs, decentralized clinical trials, real
world data (RWD) sets, and third-party app integration through
API.
About Avricore Health Inc.
Avricore Health Inc. (TSXV: AVCR) is a pharmacy
service innovator focused on acquiring and developing early-stage
technologies aimed at moving pharmacy forward. Through its flagship
offering HealthTab™ (a wholly owned subsidiary), its mission is to
make actionable health information more accessible to everyone by
creating the world’s largest network of rapid testing devices in
community pharmacies.
Contact:
Avricore Health
Inc. Hector
Bremner, CEO 604-773-8943
info@avricorehealth.com www.avricorehealth.com
Cautionary Note Regarding
Forward-Looking StatementsInformation in this press
release that involves Avricore Health's expectations, plans,
intentions or strategies regarding the future are forward-looking
statements that are not facts and involve a number of risks and
uncertainties. Avricore Health generally uses words such as
"outlook," "will," "could," "would," "might," "remains," "to be,"
"plans," "believes," "may," "expects," "intends," "anticipates,"
"estimate," "future," "positioned," "potential," "project,"
"remain," "scheduled," "set to," "subject to," "upcoming," and
similar expressions to help identify forward-looking statements. In
this press release, forward-looking statements include statements
regarding: the completion of the placement and the expected timing
thereof and the Company's expected use of proceeds from the
placement; the unique features that the HealthTab™ platform offers
to pharmacists and patients. Forward-looking statements reflect the
then-current expectations, beliefs, assumptions, estimates and
forecasts of Avricore Health's management. The forward-looking
statements in this press release are based upon information
available to Avricore Health as of the date of this press release.
Forward-looking statements believed to be true when made may
ultimately prove to be incorrect. These statements are not
guarantees of the future performance of Avricore Health and are
subject to a number of risks, uncertainties and other factors, some
of which are beyond its control and may cause actual results to
differ materially from current expectations, including without
limitation: failure to meet regulatory requirements; changes in the
market; potential downturns in economic conditions; and other risk
factors described in Avricore's public filings. These
forward-looking statements speak only as of the date on which they
are made, and the Company undertakes no obligation to update them
publicly to reflect new information or the occurrence of future
events or circumstances, unless otherwise required to do so by
law.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy.
Avricore Health (TSXV:AVCR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avricore Health (TSXV:AVCR)
Historical Stock Chart
From Apr 2023 to Apr 2024